Respiratory Syncytial Virus Market to Reach USD 4.54 Billion by 2033 as Global Uptake of Next-Generation Vaccines & Monoclonal Antibodies Accelerates

AUSTIN, Texas and TOKYO, Dec. 1, 2025 /PRNewswire/ -- According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR of 9.9% during 2025–2033.

This surge is driven by unprecedented clinical momentum in RSV prevention-including the world's first adult RSV vaccines, dramatic expansion of monoclonal antibody prophylaxis in infants, and global recognition of RSV as a major public health priority. With RSV responsible for more than 33 million lower respiratory infections and 118,000 infant deaths annually, the market is transitioning from a long-standing therapeutics gap to a rapidly evolving vaccine-led era.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/respiratory-syncytial-virus-market 

Browse in-depth TOC on "Respiratory Syncytial Virus (RSV) Market"
62 – Tables
57 – Figures
159 – Pages

A New Vaccination Era: Why the RSV Market Is Scaling Faster Than Ever Before

In the past two years, RSV has shifted from being an overlooked seasonal virus to one of the most aggressively targeted infectious diseases in the pharmaceutical pipeline. Major drivers shaping the market include:

1. First-Ever Adult RSV Vaccines Transform the Market

GSK's Arexvy and Pfizer's Abrysvo-approved for adults ≥60 and pregnant women-have created a multi-billion-dollar opportunity in elder immunization and maternal immunization.

2. Breakthrough Monoclonal Antibody Prophylaxis for Infants

Nirsevimab (Sanofi/AstraZeneca) is disrupting infant protection with only one dose per RSV season, expanding coverage by 5x compared with earlier products like palivizumab.

3. Escalating RSV Hospitalizations Across Age Groups

An aging demographic, rising comorbidities, and viral seasonality shifts have increased hospital RSV admissions by 22% YoY in the U.S. and several Asian nations.

4. Pipeline Acceleration in Antivirals

Multiple oral and inhaled antiviral candidates from global pharma companies aim to reduce severe RSV outcomes across all age groups.

Combined, these factors position RSV as the fastest-growing respiratory infection market globally-second only to influenza.

Market Segmentation

By Drug Class (Vaccines, Monoclonal Antibodies, Antivirals)

Vaccines

Vaccines represented the largest segment in 2024, contributing 56% (USD 1.09 billion) of global revenue. Adult RSV vaccination and maternal immunization programs are expanding rapidly across the U.S., Japan, Europe, and select Asia-Pacific markets.

Monoclonal Antibodies

Monoclonal antibodies accounted for 33% (USD 644 million) of the market. Nirsevimab's high-efficacy, single-dose seasonal protection has dramatically expanded infant immunization eligibility and uptake.

Antivirals

Antivirals held 11% (USD 214 million). Oral and inhaled antivirals remain essential for high-risk adults and immunocompromised patients, with strong pipeline potential expected to increase segment share by 2030.

By Age Group (Infants & Children, Adults, Geriatric)

Infants & Children

This segment accounted for 48% (USD 936 million) of 2024 global revenue.

Pediatric RSV remains the primary disease burden, with infants <6 months making up the majority of hospital admissions and ICU stays.

Adults

Adults represented 29% (USD 566 million), driven by new RSV vaccine approvals for older adults and immunocompromised populations.

Geriatric

The geriatric segment (aged ≥65) accounted for 23% (USD 448 million), reflecting high susceptibility to lower respiratory illnesses, severe complications, and hospitalization.

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies)

Hospital Pharmacies

Hospital pharmacies captured 62% (USD 1.21 billion) of revenue as severe RSV cases-including infants and the elderly-are managed through hospital-based vaccination, monoclonal antibody programs, and inpatient antiviral administration.

Retail Pharmacies

Retail pharmacies represented 38% (USD 741 million), largely driven by adult RSV vaccinations delivered through community pharmacies, primary care clinics, and maternal immunization providers.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 Reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market 

Regional Analysis

United States: The World's Largest RSV Market

The U.S. accounted for 44% (USD 858 million) of global RSV revenues in 2024.

Key U.S. Market Indicators

• Adult RSV vaccine uptake increased >34% during the 2023–24 season
• Nirsevimab adoption grew 5.2x faster than palivizumab in the first full year
• RSV-related pediatric hospitalizations rose 19% YoY
• Maternal RSV immunization coverage increased 11% YoY

The U.S. market is projected to exceed USD 2.0 billion by 2033, driven by nationwide infant immunization programs and rapid pharmacy-based vaccination expansion.

Japan: Rising Adoption of Adult Vaccines & Infant Antibodies

Japan accounted for 7% (USD 136 million) of global revenues in 2024.

Japan Market Highlights

• RSV hospitalization rates in elderly patients increased 14% YoY
• Government-supported adult vaccination pilot programs expanded by 17%
• Pediatric RSV antibody uptake increased with hospital-led maternal care programs
• Japan's aging population (>29% over 65) remains a major driver of RSV therapeutic demand

Japan is projected to reach USD 360+ million by 2033 as adult vaccine coverage accelerates.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market 

Competitive Landscape

Pfizer Inc.

• 2023 Revenue: USD 58.5 billion
• Vaccine Segment: USD 6.7 billion
• RSV vaccine Abrysvo is expanding into adult and maternal immunization markets.

GSK plc

• 2023 Revenue: USD 38.6 billion
• Vaccines Division: USD 11.4 billion
• Arexvy became the first FDA-approved RSV vaccine for older adults and posted record growth in its first year.

Moderna, Inc.

• 2023 Revenue: USD 6.8 billion
• mRNA Vaccine Portfolio Contribution: 95% of total revenue
• Developing mRNA-based RSV vaccines with multi-strain immunization potential.

AstraZeneca plc

• 2023 Revenue: USD 45.8 billion
• Vaccines & Immune Therapies Division: USD 5.9 billion
• Co-developer of nirsevimab, the market's leading infant monoclonal antibody.

Sanofi S.A.

• 2023 Revenue: USD 51.9 billion
• Vaccines Division (Sanofi Pasteur): USD 8.2 billion
• Global commercialization partner for nirsevimab, a major growth engine in the RSV market.

Merck & Co., Inc.

• 2023 Revenue: USD 60.1 billion
• Vaccines Business: USD 9.7 billion
• Advancing RSV vaccine candidates focused on pediatric and adult populations.

The Future of RSV Therapeutics: What will Reshape the Market Through 2033

The RSV therapeutics landscape is evolving faster than any other respiratory market. Key developments expected by 2033 include:

• Universal RSV vaccines combining maternal, infant, and adult protection
• Next-generation monoclonal antibodies supporting all pediatric age groups
• mRNA-based RSV immunizations enabling multi-season protection
• Combination viral vaccines (RSV + influenza + COVID-19)
• Home-based RSV diagnostics accelerating early antiviral treatment
• AI-driven RSV season prediction models supporting vaccine allocation
• Stronger pediatric vaccination mandates expanding global market size

Related Report:

1. Respiratory Monitoring Devices Market Size to Nearly Double from US$4.6 B in 2022 to US$9.3 B by 2030 - 9.3% CAGR Fuels Uptake.
2. Respiratory Care Devices Market Size to Grow from US $24.4 B in 2024 to US $39.2 B by 2030 - Riding an 8%+ CAGR on Rising Respiratory Diseases.
3. COVID-19 Vaccine Market Size to Grow from US$13.43 B in 2024 to US$29.98 B by 2033 - Nearly 2.2× Growth Ahead at 9.8% CAGR.
4. Ebola Virus Infection Market Poised to Expand Sharply Through 2031 - Strong Growth in Vaccines & Therapeutics Expected.
5. Zika Virus Therapeutics Market Size to Grow from US$19.1 B in 2024 to US$23.9 B by 2030 - Rising Outbreaks & Vaccine R&D Fuel Growth.

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.

Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: [email protected] 

Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg

SOURCE DataM Intelligence 4 Market Research LLP